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Abstract 
Purposes: To study the ability of gp96 to induce specific CTL response and its protective effect against AFP-
producing tumor, a recombinant vaccine alpha-fetoprotein (AFP)-glycoprotein (gp96) complex was constructed. 
Material/Methods: A recombinant peptide vaccine was constructed by conjugating mouse alpha-fetoprotein to 
glycoprotein 96. By way of intracutaneous injection, mice were primed and boosted with recombinant vaccine 
mAFP/gp96, whereas single mAFP or gp96 injection as controls. The ELISPOT and ELISA were used to measure the 
frequency of cells producing the cytokine IFN-gama in splenocytes and the level of anti-AFP antibody in serum from 
immunized mice respectively. In vivo tumor challenge was carried out to assess the immune effect of the 
recombinant vaccine. Results: By recombinant mAFP/gp96 vaccine immunization, the number of splenic cells 
producing IFN-gama and the level of anti-AFP antibody in serum were significantly higher in mAFP/gp96 group than 
those in mAFP and gp96 groups (122.50±9.30 IFN-gama spots/106 cells vs 46.40f10.32 IFN-gama ҏspots/106 cells, 
12.14f7.33 IFN-gama ҏspots/106 cells, P<0.01; 164.52f11.22 μg/mL vs 56.32f8.23 μg/mL, 7.56f3.47 μg/mL, 
P< 0.01). The tumor volume in mAFP/gp96 group was significantly smaller than that in mAFP and gp96 groups 
(32.46±6.35 mm3 vs 384.16±11.43 mm3, 832.54±12.72 mm3, P< 0.01). Conclusions: The study further confirmed 
the function of glycoprotein 96’s immune adjuvant. Sequential immunization with recombinant mAFP/gp96 vaccine 
could generate effective specific antitumor immunity on AFP-producing tumor. The recombined mAFP/gp96 vaccine 
may be suitable for serving as an immunotherapy for hepatocellular carcinoma. 
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The incidence of hepatocellular carcinoma (HCC) is increasing worldwide and accounts for as many as 
1.2 million deaths annually. It is also rising rapidly in China because of hepatitis B and C infections [1,2]. 
Although surgery and liver transplantation are the effective therapy, most patients lost chance due to 
diagnosis at a late stage or underlying liver insufficiency in the setting of cirrhosis [2]. Novel therapies for 
HCC should be developed. A combined therapy is likely to prolong patients’ life and living quality. 
Much attention is attracted to tumor active immunity which purpose is to induce hosts’ immune attack 
to tumor cells. 80% of HCC have a high expressing rate of alpha-fetoprotein (AFP), which could serve as 
a target for immunotherapy [3,4]. AFP is an oncofetal protein during HCC development which could 
generate weaker and less reproducible antitumor protection. How to enhance its immunity is an interesting 
issue. A recombinant vaccine approach may be a good method [5,6]. A number of groups have shown that 
superior levels of T-cell immunity could be generated using a heterogeneous prime-boost strategy, in 
which animals are primed and boosted with a palsmid vector encoding the stimulating molecule and 
targeted peptides [4-6]. In many of these vaccine models [7-9], glycoprotein 96 combined with certain 
antigen prime enhanced immunogenicity, presumably through processing and presenting the antigen to 
host antigen presenting cells (APCs). In the present study, we investigated whether the immunogenecity 
of AFP could be improved by presenting to APCs through gp96 molecules. We constructed a recombinant 
vaccine containing the molecule chaperon-gp96 and AFP protein. Then primimg mice with the 
recombinant vaccine, we elicited robust strong protective immunity. 
2.Materials and Methods 
2.1.AFP, gp96 and conjugation 
Mouse AFP was purchased from the GenWay Biotech, Inc. (San Diego, CA). Lyophilized material 
was resuspended in sterile distilled water at 10 mg/ml, aliquoted, and stored at 70°C until use. 
Balb/c mouse glycoprotein 96 (gp96) was expressed from a recombinant Escherichia coli K12 strain 
harbouring plasmid pUC119, and purified by gp96 polyclonal antibody- affinity chromatography. 
One milligram each of AFP was coupled to 1 mg of gp96 in the presence of 0.2% glutaraldehyde for 2 
h, and then dialysed against PBS overnight. Aliquots of each conjugate were stored at -70°C until use. 
2.2. Mice and cell line  
Balb/c mice were provided by Department of Experimental Animal Center at Xian Jiaotong University. 
The investigation was approved by the Ethics Committee on animal Study at Shaanxi University of 
Chinese Medicine (2004-4B). mAFP-producing H22 mice hepatocellular carcinoma cells were maintained 
in RPMI 1640 (life Technologies, Inc.) with 10% fetal bovine serum (Hyclone Technologies, Inc.). The 
supernatants were detected by AFP immunoradiation (Institute of Nuclear Sciences, Beijing) following the 
kit’s procedure. 
2.3. Mice immunized with recombinant mAFP-gp96 complex 
 Fifty female Balb/c mice were divided into mAFP/gp96 group, mAFP group, gp96 group and empty 
group, PBS control group. Every group had 10 mice. Before injection, each group was diluted in saline to 
100μg/100μl. Various groups were injected into the left anterior intracutaneous (i.c.) of mice. Priming 
and boosting was performed with 10μg mAFP or mAFP/gp96, whereas gp96 and PBS were used as 
controls. A 0.3 insulin syringe with a 25-gauge 0.5-inch-long needle was used for the i.c. injections. Mice 
were boosted i.c. with above proteins twice at 2 weeks intervals after the first priming. 
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2.4. ELISPOT and ELlSA assay  
 The ELISPOT was used to measure the frequency of cells producing the cytokine IFN-Ȗ in 
splenocytes harvested from immunized mice. Two weeks after last immunization, splenocytes were 
harvested and restimulated directly in anti-IFN-Ȗ monoclonal antibody (PharMingen) coated ELISPOT 
plate wells in vitro with 5μg/ml of AFP containing 10% fetal bovine serum, 10 units/ml of human 
interleukin-2. The plates were incubated at 37͠ for 24h. The plates were then washed and incubated with 
a biotin-conjugated secondary antibody and then developed. The color spots, representing cytokine 
producing cells, were counted under a dissecting microscope. To detect the level of anti-AFP antibody in 
mice, we examined the serum of mice tail vein after the last immunization by ELISA using alpha-
fetoprotein ELISA kits  (Biotinge Biomedicine Co, LTD., Beijing) following the manufacturer’s package 
insert procedure. 
2.5. In vivo tumor challenge   
Another fifty female Balb/c mice were grouped and immunized as above. Tumor challenge was 
performed 2 weeks after the last immunization with 1×105 H22 cells in a single cell suspension per 
animal from tumors progressively growing in syngeneic mice. H22 tumor cells for challenge were washed 
after enzymatic digestion and resuspended in 0.2 ml of PBS per animal to be injected s.c. into the left 
flank, while empty and PBS were used as controls. The sizes of tumors were assessed three times a week 
using calipers. Tumor volume was approximated by the following calculation: 4/3 ʌ r3 (r = radius). 
2.6. Statistical anlysis 
Results were expressed as mean ± SD. The frequencies of IFN-Ȗ-producing splenic cells were valued 
usingǿ2 test. The Student t test was performed to analyze the significance of differences between final 
tumor volumes of different groups of animals. P<0.05 was considered statistically significant. 
3.Results 
3.1.Prime-boost vaccines generate AFP T-cells responses and anti-AFP antibody in Balb/c mice  
Immunization of Balb/c mice with recombinant mAFP/gp96 vaccine elicited much more strong T-cells 
responses than mAFP group, whereas an i.c. vaccination with gp96 and PBS groups produced a small one 
(122.50±9.30 IFN-Ȗ ҏspots/106 cells vs 46.40r10.32 IFN-Ȗ ҏspots/106 cells, 12.14r7.33 IFN-Ȗ ҏspots/106 
cells, P<0.01). Recombinant mAFP/gp96 vaccine immunized mice also produced higher level of anti-AFP 
antibody than mAFP group, while gp96 and PBS groups produced a lower one (164.52r11.22 μg/mL vs 
56.32r8.23 μg/mL, 7.56r3.47 μg/mL, P< 0.01) (Table 1). 
Table 1  Spots of IFN-Ȗ-producing splenic cells and level of anti-AFP antibody in mice 
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Groups mAFP/gp96 mAFP gp96 Empty  PBS   
Spots 
(106 cells) 
122.50± 
9.30b 
46.40± 
10.32c 
12.14± 
7.33d 
6.87± 
2.74 
6.54± 
2.46 
Anti-AFP 
(μg/mL) 
164.52± 
11.22ab 
56.32± 
8.23c 
7.56± 
3.47d 
5.67± 
2.59 
4.92± 
2.35 
aP<0.01, VS  group c; bP<0.01, VS  group d; cP<0.01, VS  empty group; dP>0.05, VS  empty group
3.2. Boost immunization protects mice from in vivo tumor challenge  
Balb/c mice were sequentially primed and boosted with mAFP/gp96, mAFP, gp96 and PBS 
respectively. Then the mice were challenged with H22 cells. Tumor sizes were significantly smaller in 
mAFP/gp96 immunized mice than in mAFP and gp96 immunized mice (32.46±6.35 mm3 vs 
384.16±11.43 mm3, 832.54±12.72 mm3, P<0.01). Although mAFP immuninized group produced an 
obvious tumor, it was still significantly bigger than mAFP/gp96 group (384.16±11.43 mm3 vs 32.46±6.35 
mm3, P<0.01) (Table 2). 
Table 2  Comparision of tumor growth in mice injected with H22 hepatocellular carcinoma cells 
Groups No. of tumor-bearing/No. of mice challenge   
10 days after tumor challenge /Size of 
tumor (mm3)   
20 days after tumor challenge /Size of 
tumor (mm3)   
mAFP/gp96 1/10 25.21± 5.36 a 32.46±6.35 a 
mAFP 8/10 78.34± 8.62 c 384.16±11.43     
gp96 10/10 137.32±10.63  832.54±12.72  
Empty 10/10 141.53±11.42 838.36±12.47 
PBS 10/10 142.75±12.13 840.22±13.14 
aP<0.01, VS  group c; bP<0.01, VS  group d; cP<0.01, VS  empty group; dP>0.05, VS  empty group
4.Discussion 
Recent studies on the immunodominant epitopes of AFP have provided a solution to the obstacle of 
HCC immunotherapy. AFP is produced at low serum levels after birth throughout life [1,2]. The majority 
of human HCC overexpress the oncofetal antigen AFP, Mr 69 000 glycoprotein. Despite being exposed to 
high plasma levels of this oncofetal protein during embryonic development, body has a low immunity to 
it [1,2]. Butterfield et al [10,11] recently found that four peptides of human AFP processed and presented 
in the context of HLA-A0201, could be recognized by the human T cell repertoire, and could be used to 
generate AFP-specific CTL in human T cell cultures. It was also found that murine immune system could 
generate T-cell responses to this oncofetal antigen. Therefore, it may be a better target for immunotherapy. 
But AFP immunization alone still results in lower levels of specific response and poorly reproducible 
protective immunity [4-6]. 
How to enhance host’s active immunity to AFP may be an interesting strategy for HCC therapy. 
Previous studies on AFP specific immunothereapy for HCC included AFP plasmid immunization, AFP-
transduced dendritic cells (DCs) immunization and AFP plasmid prime-AFP adenovirus boost 
immunization [10-14]. AFP plasmid immunization produced detectable but low levels of AFP specific T 
cell responses and poorly reproducible protective immunity [10,11]. Additional enhancement of the T-cell 
stimulatory effect is DCs engineered to express murine AFP demonstrated a powerful ability to generate 
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tumor-specific immune responses [12,13]. However, the need for costly cell culture procedures limited 
their wide availability for clinical use, and the unstable culture technique might yield tolerating vaccine 
[12]. AFP plasmid prime-AFP adenovirus boost immunization could engender significant AFP specific 
T-cell responses and protective immunity in mice [13,14]. But the miscellaneous procedures precluded 
their use. In the present study, we tested a novel strategy to induce antitumor immunity by a recombinant 
vaccine conjugation AFP to gp96 in mice. We found the vaccine could elicit strong AFP-specific T-cell 
responses and produced a distinctive protective effect on AFP-producing tumor, compared with other 
immunized groups. We should point out that the single vaccine mAFP also produced a definite antitumor 
immunity, but the effect was not sufficient and satisfactory than that of recombinant vaccine mAFP/gp96. 
It is of interest to note that the recombinant vaccine provoked not only the considerable stability of 
immunoprotective, but also a detectable level of anti-AFP antibody, although humoral immunity alone 
had a minor limited effect on antitumor.  
In the study, we attributed the successful alpha-fetoprotein specific T-cell responses in mice to the 
gp96 molecule by mediating APCs to efficient uptake and process of AFP. Numerous investigations had 
shown that gp96 itself had no antigenicity and its immunogenecity has been attributed to the peptides 
chaperoned carried by itself [7-9]. It has been verified that gp96 was a better molecule chaperon and 
adjuvant which could process and present weak tumor antigen to MHC-I of host APCs, eliciting specific 
T-cell response and CTL reaction [8,9]. Several studies have shown that gp96-associated peptides could 
anchor antigen on the cell membrane and directly present it to nature killer cells or Ȗį T cells as 
superantigen without being dependent on the stimulation of MHC-I molecules [15-17]. In the present 
study, tumor rejection assay demonstrated that recombinant DNA vaccine AFP/gp96 elicited strong 
specific antitumor immunity against AFP-producing H22 cells than AFP DNA vaccine. Results indicated 
that AFP immunogenicity can be improved greatly by gp96 molecule and vaccination with DNA 
encoding gp96 could increase both humoral and T-cell proliferation responses to alpha-fetoprotein. We 
attributed the successful alpha-fetoprotein specific T-cell responses in mice to the gp96 molecule by 
mediating APCs to efficient uptake and process of AFP.  
In summary, the result suggests that sequential immunization with a recombinant vaccine conjugating 
alpha-fetoprotein to glycoprotein 96 could generate effective AFP-specific T cell responses and induce 
definite antitumor effect on AFP-producing tumor, which may be suitable for some clinical testing as a 
vaccine for HCC. 
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